Latest / Moving Medicine Forward
Tumor-Agnostic: AMXT 1501 & the Future of Cancer Care
We are joined by two leaders from Aminex Therapeutics, Mark Burns, President & CSO, and Jeff Judson, VP of Strategic Planning & Investor Relations, to discuss the groundbreaking development of Aminex 1501, a novel cancer therapy that is transforming oncology. This conversation dives into the science behind this innovative therapy, its distinctive funding journey, the promising clinical trial results, and the collaboration with CTI. Listen now to explore the significance of FDA orphan drug designation and what it means for advancing innovative treatments for rare cancers.
00:10 Aminex 1501 is…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.